- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07602842
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
2. september 2026 oppdatert av: InduPro, Inc.
A Phase 1/2 Open-label Study of IDP-001 in Advanced or Metastatic Squamous Cell Lung Cancer and Other Solid Tumors
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
132
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: InduPro Inc.
- Telefonnummer: 617-798-1770
- E-post: clinicaltrials@induprotx.com
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90025
- Rekruttering
- START Los Angeles
-
Ta kontakt med:
- E-post: hopeteam@startresearch.com
-
Hovedetterforsker:
- Navid Hafez, M.D.
-
-
Florida
-
Sarasota, Florida, Forente stater, 34232
- Rekruttering
- Florida Cancer Specialists
-
Ta kontakt med:
- Telefonnummer: 941-377-9993
- E-post: clinicaltrials@flcancer.com
-
Hovedetterforsker:
- Manish Patel, M.D.
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46250
- Rekruttering
- Community Cancer Center North
-
Ta kontakt med:
- Adam Norris
- Telefonnummer: 317-621-3858
- E-post: anorris@ecommunity.com
-
Hovedetterforsker:
- Nikhil Shukla, M.D.
-
-
New York
-
Buffalo, New York, Forente stater, 14263
- Rekruttering
- Roswell Park Cancer Institute
-
Hovedetterforsker:
- Prantesh Jain, M.D.
-
Ta kontakt med:
- Telefonnummer: 1-800-767-9355
- E-post: AskRoswell@RoswellPark.org
-
Lake Success, New York, Forente stater, 11042
- Rekruttering
- START New York Long Island
-
Ta kontakt med:
- E-post: hopeteam@startresearch.com
-
Hovedetterforsker:
- Geraldine O'Sullivan-Coyne, M.D.
-
-
Texas
-
Fort Worth, Texas, Forente stater, 76104
- Rekruttering
- START Dallas Forth Worth
-
Ta kontakt med:
- E-post: hopeteam@startresearch.com
-
Hovedetterforsker:
- Salwan Al-Mutar, M.D.
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Histologically-confirmed advanced, metastatic, or recurrent solid tumors that is not amenable to surgical resection or other approved therapeutic options
- Satisfy requirements for prior treatments per tumor type as outlined in the protocol
- Measurable disease per RECIST v1.1
- Participant willing to provide tumor biopsies
- Adequate organ function
- Agree to contraception requirements as outlined in the protocol
- Life expectancy greater than 12 weeks
Exclusion Criteria:
- Any clinically significant cardiac disease
- Any clinically significant corneal disorder
- Known, active, and uncontrolled hepatitis B virus (HBV), hepatitis virus (HCV) or human immunodeficiency virus (HIV), or uncontrolled chronic or ongoing infectious requiring intravenous treatment.
- Active significant neurologic disorders
- Requires home oxygen
- Active autoimmune disease
- History or active skin disease requiring frequent treatment
- History of major immunologic reaction to prior immunoglobulin G-containing agent
- Clinically significant ascites or liver disease
- Uncontrolled diabetes or diabetic neuropathy
- Active bleeding disorders
- Participation in a concurrent clinical study in the treatment period
- Pregnant or lactating or planning to become pregnant
- Known hypersensitivity to IDP-001 or any of its ingredients
- Unresolved toxicities from previous anticancer therapy
- Has had a seizure prior to Screening
- Prior solid organ transplant or allogeneic stem cell transplant
- Current endocrinopathy
- History of Stevens-Johnson syndrome or Toxic Epidermal Necrolysis
- History or interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids
- Stroke or transient ischemic attack prior to Screening
- Participant has any other condition or illness that, in the opinion of the Investigator, may compromise participant safety, compliance, or interfere with the conduct and evaluation of the current study.
Note: Other inclusion and exclusion criteria may apply.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Phase 1 Part 1 Dose Escalation
Participants with advanced or metastatic solid tumors will receive IDP-001 as intravenous (IV) infusion.
|
IV infusion
|
|
Eksperimentell: Phase 1 Part 2 Indication Selection
Participants with a single tumor indication will receive IDP-001 as IV infusion
|
IV infusion
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Phase 1 Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) during Cycle 1
Tidsramme: 3 weeks
|
3 weeks
|
|
Phase 1 Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Dose Reduction, Dose Interruption, and Dose Discontinuation
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Duration of Response (DOR) per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Area Under the Concentration Time Curve (AUC) of IDP-001
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Maximum Observed Plasma Concentration (Cmax) of IDP-001
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Number of Participants with Anti-drug Antibodies (ADAs) in Blood
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 1: ORR per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 1: DOR per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Dose Reduction, Dose Interruption, and Dose Discontinuation
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Disease Control Rate (DCR) per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Time to Response (TTR) per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Progression Free Survival (PFS) per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Overall Survival (OS)
Tidsramme: Approximately 18 months
|
Approximately 18 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
8. juli 2026
Primær fullføring (Antatt)
1. juni 2028
Studiet fullført (Antatt)
1. desember 2028
Datoer for studieregistrering
Først innsendt
8. mai 2026
Først innsendt som oppfylte QC-kriteriene
19. mai 2026
Først lagt ut (Faktiske)
22. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
3. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
2. september 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Neoplasmer etter nettsted
- Neoplasmer
- Tarmsykdommer
- Neoplasmer etter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Kolorektale neoplasmer
- Intestinale neoplasmer
- Rektale sykdommer
- Neoplasmer i hode og nakke
- Neoplasmer, kjertel og epitel
- Neoplastiske prosesser
- Esophageal sykdommer
- Karsinom
- Neoplasmer, plateepitelceller
- Neoplasmer i spiserøret
- Anus sykdommer
- Rektale neoplasmer
- Patologiske tilstander, tegn og symptomer
- Plateepitelkarsinom i hode og nakke
- Esophageal plateepitelkarsinom
- Karsinom, plateepitel
- Neoplasma Metastase
- Neoplasmer i anus
Andre studie-ID-numre
- IDP-001-101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .